基于肠道菌群及其代谢产物短链脂肪酸防治1型糖尿病的研究进展  

Research Progress in the Prevention and Treatment of Type 1 Diabetes Mellitus Based on Intestinal Flora and Its Metabolite Short-chain Fatty Acids

作　　者：宋超杰 张小莉[1] 陈换换 SONG Chaojie;ZHANG Xiaoli;CHEN Huanhuan(Henan University of Chinese Medicine,Basic Medical School,Zhengzhou 450046,China)

机构地区：[1]河南中医药大学基础医学院,河南省郑州市450046

出　　处：《中国全科医学》2021年第17期2230-2235,2240,共7页Chinese General Practice

基　　金：河南省科技攻关项目(172102310091);河南省高等学校重点科研项目(20B310005);河南中医药大学研究生创新基金(2019KYCX037)。

摘　　要：1型糖尿病(T1DM)是由T淋巴细胞介导的胰岛β细胞被定向破坏的慢性自身免疫性疾病,多发于儿童和青少年。研究发现,肠道菌群及其代谢产物短链脂肪酸(SCFAs)在T1DM的预防和治疗中发挥重要作用,肠道菌群调节将为T1DM的防治提供新的思路和方法。本文综述了肠道菌群及其代谢产物SCFAs防治T1DM的研究进展,探究SCFAs、膳食纤维、益生菌和益生元、肠道菌群移植及中药治疗改善T1DM的研究现状,为临床应用提供参考。Type 1 diabetes mellitus is a chronic autoimmune disease in which directed destruction of pancreaticβcell mediated by T lymphocytes.It is more common in children and adolescents.Studies have shown that the intestinal flora and its metabolites short-chain fatty acids play an important role in the prevention and treatment of T1DM.The regulation of intestinal flora will provide new ideas and approaches for the prevention and treatment of T1DM.This article reviews the research progress of the intestinal flora and its metabolites SCFAs in the prevention and treatment of T1DM and explors the current research status of the T1DM improvement by SCFAs,dietary fiber,probiotics and prebiotics,intestinal flora transplantation and Chinese medicine treatment,which providing reference for clinical application.

关 键 词：糖尿病 1型 肠道菌群 短链脂肪酸 病症防治 综述 

分 类 号：R587.1[医药卫生—内分泌]